Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease

AORTA

Volumn 1, Issue 3, 2013, Pages 210-217

  Sarkar, Abdullah ^a,b   Prasad, Kailash ^c   Ziganshin, Bulat A ^a,d   Elefteriades, John A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Aortic aneurysm; Aortic disease; Screening biomarker; sRAGE

Indexed keywords

EID: 84914115910     PISSN: 23254637     EISSN: None     Source Type: Journal    
DOI: 10.12945/j.aorta.2013.13-047     Document Type: Article

References (49)

1. Control NCfIPa. WISQARS leading causes of death reports, 1999-2007. 2012; [cited 2012 April 10]; Available from: http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html
2. Elefteriades J. A. Beating a sudden killer. Sci Am: 2005; 293 64 71. 10.1038/scientificamerican0805-64
3. Hudson B. I. Wendt T. Bucciarelli L. G. Rong L. L. Naka Y. Yan S. F., et al. Diabetic vascular disease: it's all the RAGE. Antioxidants Redox Signaling: 2005; 7 1588 1600. 10.1089/ars.2005.7.1588
4. Geroldi D. Falcone C. Emanuele E. DAngelo A. Calcagnino M. Buzzi M. P., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens: 2005; 23 1725 1729. 10.1097/01.hjh.0000177535.45785.64
5. Basta G. Sironi A. M. Lazzerini G. Del Turco S. Buzzigoli E. Casolaro A., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab: 2006; 91 4628 4634. 10.1210/jc.2005-2559
6. Devangelio E. Santilli F. Formoso G. Ferroni P. Bucciarelli L. Michetti N., et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med: 2007; 43 511 518. 10.1016/j.freeradbiomed.2007.03.015
7. Santilli F. Bucciarelli L. Noto D. Cefalù A. B. Davì V. Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med: 2007; 43 1255 1262. 10.1016/j.freeradbiomed.2007.06.017
8. Emanuele E. D'Angelo A. Tomaino C. Binetti G. Ghidoni R. Politi P., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol: 2005; 62 1734 1736. 10.1001/archneur.62.11.1734
9. Montaner J. Perea-Gainza M. Delgado P. Ribo M. Chacon P. Rosell A., et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke: 2008; 39 2280 2287. 10.1161/STROKEAHA.107.505354
10. Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol: 2006; 15 57 68
11. Kalea A. Z. Schmidt A. M. Hudson B. I. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci: 2009; 116 621 637. 10.1042/CS20080494
12. Yonekura H. Yamamoto Y. Sakurai S. Petrova R. G. Abedin J. Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J: 2003; 370 1097 1109. 10.1042/BJ20021371
13. Wendt T. Harja E. Bucciarelli L. Qu W. Lu Y. Rong L. L., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis: 2006; 185 70 77. 10.1016/j.atherosclerosis.2005.06.013
14. Bucciarelli L. G. Wendt T. Qu W. Lu W. Lalla E. Rong L. L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation: 2002; 106 2827 2835. 10.1161/01.CIR.0000039325.03698.36
15. McNair E. D. Wells C. R. Qureshi A. M. Basran R. Pearce C. Orvold J., et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol: 2009; 18 187 192. 10.1055/s-0031-1278352
16. Falcone C. Emanuele E. D'Angelo A. Buzzi M. P. Belvito C. Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol: 2005; 25 1032 1037. 10.1161/01.ATV.0000160342.20342.00
17. Hudson B. I. Harja E. Moser B. Schmidt A. M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol: 2005; 25 879 882. 10.1161/01.ATV.0000164804.05324.8b
18. Lindsey J. B. Cipollone F. Abdullah S. M. McGuire D. K. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes Vasc Dis Res: 2009; 6 7 14. 10.3132/dvdr.2009.002
19. Maillard-Lefebvre H. Boulanger E. Daroux M. Gaxatte C. Hudson B. I. Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology: 2009; 48 1190 1196. 10.1093/rheumatology/kep199
20. Thorpe S. R. Baynes J. W. Millard reaction products in tissue proteins: new products and new perspectives. Amino Acids: 2003; 25 275 281. 10.1007/s00726-003-0017-9
21. Schmidt A. M. Vianna M. Gerlach M. Brett J. Ryan J. Kao J., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on endothelial cell surface. J Biol Chem: 1992; 267 14987 14997
22. Schmidt A. M. Hori O. Brett J. Yan S. D. Wautier J. L. Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb Vasc Biol: 1994; 14 1521 1528. 10.1161/01.ATV.14.10.1521
23. Ramasamy R. Schmidt A. M. Receptor for advance glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep: 2012; 9 107 116. 10.1007/s11897-012-0089-5
24. Huttunen H. J. Kuja-Panula J. Sorci G. Agneletti A. L. Donato R. Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advance glycation end products (RAGE) activation. J Biol Chem: 2000; 275 40096 40105. 10.1074/jbc.M006993200
25. Basta G. Lazzerini G. Massaro M. Simoncini T. Tanganelli P. Fu C., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation: 2002; 105 816 822. 10.1161/hc0702.104183
26. Hofmann M. A. Drury S. Fu C. Qu W. Taguchi A. Lu Y., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell: 1999; 97 889 901. 10.1016/S0092-8674(00)80801-6
27. Shaw S. S. Schmidt A. M. Banes A. K. Wang X. Stern D. M. Marrero M. B. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes: 2003; 52 2381 2388. 10.2337/diabetes.52.9.2381
28. Raucci A. Cugusi S. Antonelli A. Barabino S. M. Monti L. Bierhaus A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J: 2008; 22 3716 3727. 10.1096/fj.08-109033
29. Galichet A. Weibel M. Heizmann C. W. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun: 2008; 370 1 5. 10.1016/j.bbrc.2008.02.163
30. Zhang F. Kent K. C. Yamanouchi D. Zhang Y. Kato K. Tsai S., et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg: 2009; 250 416 423. 10.1097/SLA.0b013e3181b14a18
31. Arumugam T. Simeone D. M. Schmidt A. M. Logsdon C. D. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem: 2004; 279 5059 5065. 10.1074/jbc.M310124200
32. Norata G. D. Garlaschelli K. Grigore L. Tibolla G. Raselli S. Redaelli L., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutrition Metab Cardiovasc Dis: 2009; 19 129 134. 10.1016/j.numecd.2008.03.004
33. Qi Y. Gong F. Zhang Q. Xie C. Wang W. Fu S. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease. Arthritis Res Ther: 2012; 14 R251. 10.1186/ar4094
34. Wittkowski H. Hirono K. Ichida F. Vogl T. Ye F. Yanlin X., et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum: 2007; 56 4174 4181. 10.1002/art.23042
35. Basta G. Corciu A. I. Vianello A. Del Turco S. Foffa I. Navarra T., et al. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis: 2010; 210 614 618. 10.1016/j.atherosclerosis.2009.12.029
36. Park H. Y. Yun K. H. Park D. S. Levels of soluble receptor for advanced glycation end products in acute ischemic stroke without a source of cardioembolism. J Clin Neurol: 2009; 5 126 132. 10.3988/jcn.2009.5.3.126
37. Yokota C. Minematsu K. Tomii Y. Naganuma M. Ito A. Nagasawa H., et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci: 2009; 287 41 44. 10.1016/j.jns.2009.09.013
38. McNair E. D. Wells C. R. Mabood Qureshi A. Basran R. Pearce C. Orvold J., et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol: 2010; 33 678 685. 10.1002/clc.20815
39. Ziganshin B. A. Elefteriades J. A. Thoracic aortic diseases. In: Stergiopoulos K. Brown D. L., Eds. The Evidence-Based Cardiology Consult. New York Springer: 2014; [In Press].
40. Alexander J. J. The pathobiology of aortic aneurysms. J Surg Res: 2004; 117 163 175. 10.1016/j.jss.2003.11.011
41. El-Hamamsy I. Yacoub M. H. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol: 2009; 6 771 786. 10.1038/nrcardio.2009.191
42. Raines E. W. Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J: 1993; 69 (1 Suppl) S30 S37
43. Karnik S. K. Brooke B. S. Bayes-Genis A. Sorensen L. Wythe J. D. Schwartz R. S., et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development: 2003; 130 411 423. 10.1242/dev.00223
44. Koullias G. J. Korkolis D. P. Ravichandran P. Psyrri A. Hatzaras I. Elefteriades J. A. Tissue microarray detection of matrix metalloproteinases, in diseased tricuspid and bicuspid aortic valves with or without pathology of the ascending aorta. Eur J Cardio-Thoracic Surg: 2004; 26 1098 1103. 10.1016/j.ejcts.2004.07.050
45. Della Corte A. Quarto C. Bancone C. Castaldo C. Di Meglio F. Nurzynska D., et al. Spatiotemporal patterns of smooth muscle cell changes in ascending aortic dilatation with bicuspid and tricuspid aortic valve stenosis: focus on cell-matrix signaling. J Thoracic Cardiovasc Surg: 2008; 135 8 18, 18 e11-12. 10.1016/j.jtcvs.2007.09.009
46. Cipollone F. Iezzi A. Fazia M. Zucchelli M. Pini B. Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation: 2003; 108 1070 1077. 10.1161/01.CIR.0000086014.80477.0D
47. Hofmann Bowman M. Wilk J. Heydemann A. Kim G. Rehman J. Lodato J. A., et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res: 2010; 106 145 154. 10.1161/CIRCRESAHA.109.209486
48. Ailawadi G. Eliason J. L. Upchurch G. R. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg: 2003; 38 584 588. 10.1016/S0741-5214(03)00324-0
49. Zhao L. Moos M. P. Gräbner R. Pédrono F. Fan J. Kaiser B., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Med: 2004; 10 966 973. 10.1038/nm1099